Qué cambió
Qué cambióEl 17 de noviembre de 2026, el consejo de administración de Boston Scientific aprobó el plan de bonificación anual para 2027 y dos programas de incentivos bursátiles a largo plazo para la dirección. Simultáneamente, la empresa anunció que David S. Wichmann asumirá el cargo de director independiente principal a partir del 1 de enero de 2027.

Qué cambióBoston Scientific informó de sus resultados financieros correspondientes al tercer trimestre de 2026, finalizado el 30 de septiembre. Las ventas netas de la compañía en este periodo ascendieron a 5.138 millones de $.

Qué cambióBoston Scientific said Arthur C. Butcher will leave his role as executive vice president and group president, MedSurg and Asia Pacific, and will become a senior advisor through February 26, 2027 with a base salary of $780,000. Joe Fitzgerald is promoted to executive vice president and chief operating officer with a base salary of $1,050,000, a target bonus of 110% and a planned equity grant of $7 million.

Historial de la empresa
Octubre 2026
BOSTON SCIENTIFIC CORP: 12 recorded developments from 3 official sources in 2026-10.
- 2026-09-23: On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027. Fuente
- 2026-09-23: Mr. Butcher is expected to remain with the Company as a senior advisor from such time through February 26, 2027 (such date, or any earlier date, the “Retirement Date”). Fuente
- 2026-09-23: As a senior advisor, Mr. Butcher will receive a base salary at his current annual base salary of $780,000, prorated through the Retirement Date. Fuente
- 2026-09-23: Pursuant to the Retirement Agreement, Mr. Butcher will be entitled to payments and benefits that are materially consistent with those he is entitled to under the Company’s Executive Retirement Plan, 2026 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereund Fuente
- 2026-10-07: There are no arrangements or understandings between Mr. Bickel and any other person pursuant to which Mr. Bickel was selected as an officer, there are no family relationships between Mr. Bickel and any director or other officer of the Company, and Mr. Bickel does not have any direct or i Fuente
- 2026-10-07: Item 8.01 Other Events. A copy of the Company’s press release dated October 7, 2026, announcing the events described under Item 5.02 above is included in this filing as Exhibit 99.1. Fuente
- 2026-10-07: On October 7, 2026, Boston Scientific Corporation announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027 Fuente
- 2026-10-07: Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company's Cardiovascular business; in his current position, which he has held since May 2022, Mr. Fitzgerald oversees development and commercialization of advanced heart therapies fo Fuente
- 2026-10-07: Mr. Fitzgerald will have continued eligibility to participate in the Company's Annual Bonus Plan, with an incentive target percentage equal to 110% of his annual base salary. Fuente
- 2026-10-07: Mr. Fitzgerald will have continued eligibility to participate in the Company's Deferred Bonus Plan, under which he is able to elect to defer up to 75% of the annual bonus awarded to him for each applicable year. Fuente
- 2026-10-07: Ms. Woodworth will continue serving in her current position as Senior Vice President, Global Controller and Chief Accounting Officer, which she has held since January 2024, until March 1, 2027, at which time Ms. Woodworth will no longer serve as the Company’s Chief Accounting Officer. Fuente
- 2026-10-28: On October 28, 2026, Boston Scientific Corporation issued a press release announcing financial results for the third quarter ended September 30, 2026. Fuente
Los registros mensuales los redacta la IA a partir de los informes y fuentes oficiales verificados de cada mes (en inglés, tal como se extrajeron), y cada línea enlaza su fuente; las líneas argumentales agrupan hechos relacionados entre análisis mediante embeddings vectoriales (Amazon Titan Text Embeddings V2). Contexto provisional, no es asesoramiento de inversión.
Comparables del sector
Comparación con 36 empresas seguidas en Salud (mediana de ingresos +7,2% a/a), según datos XBRL de la SEC.
| Empresa | Últimos ingresos | Ingresos a/a | Margen operativo |
|---|
| Boston Scientific Corp BSX | 5,1 mil M $ | +1,4% | 16,1% |
| Unitedhealth Group Inc UNH | 113 mil M $ | -0,4% | 5,8% |
| Mckesson Corp MCK | 111 mil M $ | +7,6% | 1,4% |
| CVS Health Corp CVS | 108 mil M $ | +5,4% | 3,3% |
| Cigna Group CI | 73,7 mil M $ | +5,6% | 3,3% |
| Cardinal Health Inc CAH | 67,5 mil M $ | +5,5% | 1,1% |
| Elevance Health, Inc. ELV | 51,4 mil M $ | +1,4% | 2,5% |
Último periodo reportado por empresa en SEC CompanyFacts (XBRL). Los calendarios fiscales pueden diferir.
Expectativas y realidad
Abiertas
The company expects to deliver common stock shares in settlement of satisfied Performance Share Units no later than March 15, 2030.
Dicho el 17 de noviembre de 2026 · Periodo indicado: March 15, 2030 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
The company established an annual bonus plan for the performance period of January 1 to December 31, 2027.
Dicho el 17 de noviembre de 2026 · Periodo indicado: January 1 - December 31 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
The Company approved the 2027 Annual Bonus Plan for the performance year January 1, 2027 through December 31, 2027.
Dicho el 17 de noviembre de 2026 · Periodo indicado: January 1, 2027 through December 31, 2027 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Shares of common stock will be delivered no later than March 15, 2030, in settlement of performance share units if performance and eligibility criteria are met.
Dicho el 17 de noviembre de 2026 · Periodo indicado: March 15, 2030 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Boston Scientific estimates full year 2026 adjusted EPS, excluding certain charges (credits), to be $3.16 to $3.18.
Dicho el 28 de octubre de 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Boston Scientific estimates full year 2026 net sales growth versus the prior year period to be approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis.
Dicho el 28 de octubre de 2026 · Periodo indicado: full year 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Mostrar todas (11)
Boston Scientific Corporation estimates Q4 2026 reported net sales growth/(decline) to be between (3.0)% and (1.0)%, and full year 2026 reported growth to be ~4.25%.
Dicho el 28 de octubre de 2026 · Periodo indicado: Q4 and FY 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Boston Scientific Corporation estimates Q4 2026 operational net sales growth/(decline) to be between (3.0)% and (1.0)%, and full year 2026 operational growth to be ~3.75%.
Dicho el 28 de octubre de 2026 · Periodo indicado: Q4 and FY 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Boston Scientific estimates fourth quarter 2026 net sales to decline versus the prior year period by approximately (3.0) to (1.0) percent on a reported and organic basis.
Dicho el 28 de octubre de 2026 · Periodo indicado: fourth quarter of 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Boston Scientific Corporation estimates Q4 2026 organic net sales growth/(decline) to be between (3.0)% and (1.0)%, and full year 2026 organic growth to be ~3.75%.
Dicho el 28 de octubre de 2026 · Periodo indicado: Q4 and FY 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Boston Scientific estimates fourth quarter 2026 adjusted EPS, excluding certain charges (credits), to be $0.77 to $0.79.
Dicho el 28 de octubre de 2026 · Periodo indicado: Fourth Quarter 2026 · Fuente · Nuestro análisis
Aún no contrastada con informes posteriores.
Lo que la dirección dijo que cabía esperar en los propios documentos de la empresa (objetivos, planes, previsiones; en inglés, tal como se extrajo), con la fecha y el periodo indicado. Las valoraciones las escribe la IA a partir de informes posteriores: provisionales, no revisadas por un editor, y un informe posterior coherente no es una prueba. La decisión de un editor las sustituye.
Cambios en los factores de riesgo
El 10-Q del 2 de noviembre de 2026 comparado con el 10-Q del 3 de agosto de 2026: párrafos de riesgo añadidos o eliminados, citados tal como se presentaron. SEC
Añadidos (24)
- Net increase (decrease) in commercial paper | 1,003 | | | (196)
- On September 11, 2026, we entered into a definitive agreement to acquire 100 percent of Jiangsu TingSN Technology Co., Ltd (TingSN), a privately held medical device company headquartered in China, that develops and commercializes catheter-based medical technologies for cardiac and vascular interventions, including diagnostic intravascular and intracardiac ultrasound imaging solutions. The purchase price consists of an upfront cash payment of approximately $250 million and up to an additional $75 million in future payments upon achievement of commercialization and sales milestones. The…
- On October 2, 2026, we entered into an agreement with funds managed by Blackstone Life Sciences Advisors L.L.C. (Blackstone) to co-fund development activities for our VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System for the treatment of patients with acute myocardial infarction with cardiogenic shock (the Product). Under the agreement, we are eligible to receive up to $455 million from contract inception through regulatory approval of the Product in the United States, unless otherwise terminated, based on qualifying development costs incurred. As there is substantive…
Eliminados (8)
- Fair value of contingent consideration | 100 | | | 98 | | | 38
- | $ | 220 | | | $ | 255 | | | $ | — | | | $ | 475 | | | $ | 1,092 | | | $ | 181 | | | $ | — | | | $ | 1,273
- | $ | — | | | $ | 1,198 | | | $ | 257 | | | $ | 1,455 | | | $ | — | | | $ | 1,308 | | | $ | 392 | | | $ | 1,700
Detectado comparando los dos informes párrafo a párrafo, sin IA. Un riesgo nuevo o eliminado no es por sí mismo señal de problemas.
Hechos de gobierno corporativo
Documentos sobre cómo se dirige la empresa: cambios de auditor, reformulaciones, cambios en la dirección, informes tardíos, exclusiones de cotización, participaciones del Schedule 13D y cartas de la SEC, de la más reciente a la más antigua.
| Fecha | Hecho | Declaración |
|---|
| 17 de noviembre de 2026 | Salida o nombramiento de un consejero o directivo (8-K punto 5.02) | 8-K |
| 7 de octubre de 2026 | Salida o nombramiento de un consejero o directivo (8-K punto 5.02) | 8-K |
| 23 de septiembre de 2026 | Salida o nombramiento de un consejero o directivo (8-K punto 5.02) | 8-K |
| 8 de septiembre de 2026 | Incidente de ciberseguridad relevante (8-K punto 1.05) | 8-K |
Tal como se presentó a la SEC, leído por código. Una carta de comentarios forma parte de la revisión habitual de la SEC y no implica por sí sola un problema; el punto 5.02 incluye nombramientos y salidas; el Form 25 puede referirse a un bono u otra clase de valores.
Grandes fondos (13F)
| Fondo | Acciones | Valor | Cambio en acciones | Trimestre |
|---|
| BlackRock | 125.556.119 | $5.480.524.601 | -3,2% | T3 2026 |
| State Street | 67.322.516 | $2.938.627.823 | -4,0% | T3 2026 |
| Fidelity (FMR) | 40.115.549 | $1.751.043.728 | -12,2% | T3 2026 |
| Geode Capital Management | 34.468.097 | $1.497.660.949 | +3,1% | T3 2026 |
| D. E. Shaw & Co. | 21.245.733 | $927.376.246 | -16,5% | T3 2026 |
| Wellington Management | 21.004.216 | $916.834.028 | +37,3% | T3 2026 |
| Norges Bank (Norway's sovereign fund) | 21.170.029 | $903.536.838 | — | T2 2026 |
| Two Sigma Investments | 20.006.783 | $873.296.078 | +3,3% | T3 2026 |
| Capital Research Global Investors | 17.241.496 | $752.597.850 | +21,6% | T3 2026 |
| Citadel Advisors | 7.812.630 | $341.021.300 | +56,6% | T3 2026 |
| Renaissance Technologies | 1.765.305 | $77.055.563 | -26,8% | T3 2026 |
| Millennium Management | 1.121.537 | $27.130.090 | -79,4% | T3 2026 |
| Bridgewater Associates | 437.208 | $19.084.129 | -1,1% | T3 2026 |
| T. Rowe Price | 6.750.795 | $294.673 | -4,5% | T3 2026 |
De los informes trimestrales 13F-HR de los grandes fondos que seguimos, tal como se presentaron. Los fondos informan hasta 45 días después del cierre del trimestre, por lo que las posiciones pueden haber cambiado. Cambio: frente al trimestre anterior del mismo fondo. No es una recomendación.